Search results
7 lip 2018 · Noninvasive ventilation (NIV) has become the standard of care for respiratory support in patients with ALS. NIV use has demonstrated survival benefit and improved quality of life vs standard of care.
7 paź 2021 · In our study, the risk of early death was nearly three times higher in FTD-ALS patients than in ALS patients alone, and the presence of executive dysfunction in non-demented ALS patients might affect the longevity of survival.
Although clinical presentations can vary, there is no cure for ALS, and the disease is universally terminal, with most patients dying of respiratory complications. Patients die, on average, within 3 to 5 years of diagnosis, unless they choose to undergo tracheostomy, in which case, they may live, on average, 2 additional years.
19 sty 2023 · A comprehensive, multidisciplinary approach to ALS respiratory care may minimize hospitalizations for acute respiratory failure, reduce need for emergent tracheostomy, improve patient-reported outcome measures, and facilitate developing clinical research initiatives.
Fifteen years have elapsed since noninvasive ventilation was shown to improve survival and quality of life for patients with amyotrophic lateral sclerosis (ALS). 1 Since that time, extraordinary technological advances in home-assisted ventilation and airway clearance devices have dramatically expanded opportunities to optimize respiratory care ...
4 paź 2014 · Our study is based on a prospective, population-based cohort of ALS patients. The aim of our paper is to identify prognostic factors at time of diagnosis related to fast disease progression and early death within 12 months after first diagnosis.
15 kwi 2015 · ALS leads to death in 15 to 20 months after diagnosis in 50 % of patients [2 ••], generally due to respiratory failure. An older age and bulbar involvement at onset are the main negative prognostic factors. Ten percent survives more than 10 years.
